8-K: Stereotaxis Secures $50M At-The-Market Equity Offering

Stereotaxis, Inc. has entered into a sales agreement with Roth Capital Partners, LLC to sell up to $50 million of common stock through an at-the-market offering.

Summary

• Entered into a Sales Agreement with Roth Capital Partners, LLC on August 29, 2025, allowing for the sale of common stock.
• May sell shares with an aggregate sales price of up to $50,000,000 through an 'at-the-market' (ATM) offering.
• Net proceeds from the sale of shares are intended for working capital, research and development, and other general corporate purposes, including accelerated commercialization of the innovation pipeline.
• Roth Capital Partners, LLC will act as the sales agent and/or principal, receiving a placement fee of up to 3.0% of the gross sales price.
• The company is not obligated to make any sales, with actual sales dependent on market conditions and capital needs.

Sentiment

Score: 7

Explanation: The capital raise provides significant financial flexibility for Stereotaxis to fund working capital, R&D, and accelerate its innovation pipeline, which are positive for long-term growth. However, the potential for shareholder dilution and market-dependent sales introduce some uncertainty.

Positives

• Provides access to up to $50 million in capital, enhancing financial flexibility for strategic investments.
• Funds working capital, research and development, and accelerates the commercialization of the innovation pipeline, supporting future growth.
• The 'at-the-market' structure allows for opportunistic capital raising based on favorable market conditions, minimizing immediate dilution impact compared to a single large offering.

Negatives

• Potential for dilution of existing shareholders as new common stock will be issued over time.
• Sales are contingent on market conditions, meaning the full $50 million may not be raised, or shares may be sold at potentially unfavorable prices.
• Incurs costs including a placement fee of up to 3.0% of gross sales and reimbursement for agent's legal and other specified expenses.

Risks

• Sales of common stock under the agreement are not guaranteed and depend on prevailing market conditions and the company's capital requirements.
• The issuance of additional shares could dilute the ownership interest of current shareholders.
• The company is not obligated to make any sales, which means the anticipated capital may not be fully realized.

Future Outlook

The company intends to use the net proceeds from the sale of shares for working capital, research and development, and other general corporate purposes, including the accelerated commercialization of its innovation pipeline, signaling a focus on growth and product development.

Management Comments

• The company intends to use the net proceeds for working capital, research and development, and other general corporate purposes, including the accelerated commercialization of our innovation pipeline.

Industry Context

At-the-market offerings are a common capital-raising tool for growth-oriented companies, particularly in the medical device and robotics sectors, which often require substantial ongoing investment in research and development and commercialization efforts to remain competitive and bring new innovations to market.

Stakeholder Impact

• Shareholders: Potential for dilution from new share issuance, balanced by the potential for increased company value through funded growth initiatives.
• Employees: Continued investment in R&D and commercialization could lead to job stability and growth opportunities.
• Customers: Accelerated innovation pipeline may result in new or improved products and services.
• Creditors: A strengthened balance sheet from the capital raise could improve the company's creditworthiness.

Next Steps

• Potential future sales of common stock under the Sales Agreement, subject to market conditions and capital needs.
• Continued investment in research and development to advance the innovation pipeline.
• Accelerated commercialization efforts for new products and technologies.

Key Dates

Recommendation

The at-the-market offering provides Stereotaxis with crucial capital to fund its strategic initiatives, including R&D and commercialization, which are vital for future growth in the competitive medical robotics sector. While there is a potential for short-term dilution, the long-term benefits of a strengthened balance sheet and accelerated innovation pipeline could be significant. Investors should monitor the execution of the capital deployment and the impact on the innovation pipeline.

Keywords

Stereotaxis, STXS, ATM offering, equity raise, capital raise, medical devices, robotics, cardiac ablation, Roth Capital Partners